Eventide Asset Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $32.9M | Sell |
1,037,000
-605,559
| -37% | -$16.5M | 0.54% | 63 |
|
|
2025
Q4 | $44.6M | Sell |
1,642,559
-216,536
| -12% | -$5.7M | 0.7% | 49 |
|
|
2025
Q3 | $48.1M | Buy |
1,859,095
+502,909
| +37% | +$11.7M | 0.79% | 41 |
|
|
2025
Q2 | $27.6M | Sell |
1,356,186
-2,398,607
| -64% | -$46.7M | 0.48% | 75 |
|
|
2025
Q1 | $68.2M | Buy |
3,754,793
+1,533
| +0% | +$34.3K | 1.36% | 17 |
|
|
2024
Q4 | $94.8M | Buy |
3,753,260
+421,255
| +13% | +$11.4M | 1.73% | 8 |
|
|
2024
Q3 | $113M | Buy |
3,332,005
+4,873
| +0.1% | +$186K | 1.95% | 9 |
|
|
2024
Q2 | $123M | Buy |
3,327,132
+208,045
| +7% | +$7.85M | 2.11% | 9 |
|
|
2024
Q1 | $131M | Sell |
3,119,087
-510,926
| -14% | -$21M | 2.05% | 8 |
|
|
2023
Q4 | $144M | Buy |
3,630,013
+2,030,013
| +127% | +$59.7M | 2.35% | 5 |
|
|
2023
Q3 | $44M | Buy |
1,600,000
+222,260
| +16% | +$6.97M | 0.79% | 44 |
|
|
2023
Q2 | $46.7M | Hold |
1,377,740
| – | – | 0.79% | 43 |
|
|
2023
Q1 | $49.6M | Sell |
1,377,740
-85,310
| -6% | -$3.68M | 0.91% | 35 |
|
|
2022
Q4 | $65.2M | Sell |
1,463,050
-328,750
| -18% | -$11.7M | 1.29% | 27 |
|
|
2022
Q3 | $50.4M | Buy |
1,791,800
+346,100
| +24% | +$10.6M | 0.99% | 37 |
|
|
2022
Q2 | $39M | Hold |
1,445,700
| – | – | 0.83% | 44 |
|
|
2022
Q1 | $49.2M | Buy |
1,445,700
+206,800
| +17% | +$6.61M | 0.77% | 45 |
|
|
2021
Q4 | $47.9M | Buy |
1,238,900
+110,900
| +10% | +$4.83M | 0.61% | 54 |
|
|
2021
Q3 | $60.9M | Sell |
1,128,000
-980,908
| -47% | -$46M | 0.8% | 40 |
|
|
2021
Q2 | $70.5M | Buy |
2,108,908
+46,475
| +2% | +$1.28M | 0.95% | 39 |
|
|
2021
Q1 | $42.5M | Buy |
2,062,433
+225,325
| +12% | +$5.17M | 0.63% | 60 |
|
|
2020
Q4 | $32.2M | Buy |
1,837,108
+1,330,929
| +263% | +$24M | 0.49% | 66 |
|
|
2020
Q3 | $7.51M | Buy |
506,179
+42,844
| +9% | +$502K | 0.15% | 105 |
|
|
2020
Q2 | $6.02M | Buy |
+463,335
| New | +$2.05M | 0.13% | 101 |
|
|
2016
Q1 | – | Sell |
-28,033
| Closed | -$6.59M | – | 140 |
|
|
2015
Q4 | $6.59M | Buy |
28,033
+12,780
| +84% | +$2.79M | 0.33% | 73 |
|
|
2015
Q3 | $2.41M | Sell |
15,253
-3,994
| -21% | -$1.13M | 0.14% | 95 |
|
|
2015
Q2 | $7.28M | Hold |
19,247
| – | – | 0.39% | 62 |
|
|
2015
Q1 | $8.05M | Hold |
19,247
| – | – | 0.61% | 60 |
|
|
2014
Q4 | $5.27M | Hold |
19,247
| – | – | 0.58% | 61 |
|
|
2014
Q3 | $3.74M | Hold |
19,247
| – | – | 0.52% | 62 |
|
|
2014
Q2 | $4.71M | Hold |
19,247
| – | – | 0.64% | 59 |
|
|
2014
Q1 | $5.1M | Buy |
19,247
+2,114
| +12% | +$809K | 0.79% | 53 |
|
|
2013
Q4 | $6.22M | Buy |
+17,133
| New | +$6.6M | 1.92% | 26 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Eventide Asset Management's CLDX Position: Q1 2026 in Review
Eventide Asset Management reduced its Celldex Therapeutics (CLDX) stake by 37% in Q1 2026, selling an estimated $16.5M and leaving 1,037,000 shares worth $32.9M. The position accounts for 0.54% of the portfolio, ranked #63.
Eventide Asset Management first reported a position in CLDX in Q4 2013 and has held it in 33 quarters since. The position peaked at $144M in Q4 2023. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Eventide Asset Management held 1,037,000 shares of Celldex Therapeutics worth $32.9M as of Q1 2026.
- Eventide Asset Management sold 605,559 Celldex Therapeutics shares in Q1 2026, an estimated $16.5M.
- Celldex Therapeutics made up 0.54% of Eventide Asset Management's portfolio in Q1 2026, its #63 holding.
- Eventide Asset Management first reported a position in Celldex Therapeutics in Q4 2013 and has held it in 33 quarters since.
- Eventide Asset Management's Celldex Therapeutics position peaked at $144M in Q4 2023.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.